Suchergebnisse - "Pu, Xingxiang"

PubPharm (67)

1

Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment : A multicenter, randomized phase II trial

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Pu, X. | Xiao, Z. | Li, J. | +17

2

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

enthalten in: British journal of cancer | 2024

von Chen, B. | Yao, W. | Li, X. | +21

3

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

enthalten in: Thoracic cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +98

4

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

enthalten in: Global medical genetics | 2024

von Xu, C. | Wang, Q. | Wang, D. | +98

5

Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung) : a single-arm phase II study

enthalten in: EClinicalMedicine | 2024

von Pu, X. | Lin, G. | Xiao, M. | +15

6

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

enthalten in: Thoracic Cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +103

7

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer

enthalten in: Thoracic cancer | 2023

von Huang, D. | Lin, G. | Chu, Q. | +98

8

Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China

enthalten in: Thoracic cancer | 2023

von Pu, X. | Xu, C. | Wang, Q. | +98

9

Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer : A Systematic Review and Meta-analysis of Randomized Controlled Trials

enthalten in: American journal of clinical oncology | 2023

von Yu, S. | Zhai, S. | Gong, Q. | +4

10

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation : an ambispective cohort study

enthalten in: BMC cancer | 2023

von Pu, X. | Zhou, Y. | Kong, Y. | +6

1
2
3
4
5
6
7
Nächster »
[7]